Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
about
Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prosteinA phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neuImmunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patientsImmunobiology and immunotherapy in genitourinary malignanciesA Perspective of Immunotherapy for Prostate CancerPerspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigmImmune Infiltration and Prostate CancerImmunotherapy for prostate cancer: recent developments and future challengesEvolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223Therapeutic cancer vaccines: past, present, and futureFrom bench to bedside: immunotherapy for prostate cancerEndpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesCancer immunotherapy comes of ageThe dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape.Advances in preclinical investigation of prostate cancer gene therapy.CD40-activated B cells induce anti-tumor immunity in vivo.Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis.Vaccines as monotherapy and in combination therapy for prostate cancer.Cancer immunotherapy: sipuleucel-T and beyond.The nanomaterial-dependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus.Dendritic cell-based immunotherapy for prostate cancer.Co-expression of HIV-1 virus-like particles and granulocyte-macrophage colony stimulating factor by GEO-D03 DNA vaccine.The treatment challenge of hormone-refractory prostate cancer.Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens.Prostate-specific antigen vaccines for prostate cancer.DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.Spinning molecular immunology into successful immunotherapy.Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells.Dendritic cell vaccines containing lymphocytes produce improved immunogenicity in patients with cancer.Exploiting synergy: immune-based combinations in the treatment of prostate cancer.Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumorsSipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer.Castration-resistant prostate cancer: new science and therapeutic prospects.Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatmentManagement of high-risk localized prostate cancer.A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.Evaluation of an α synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease
P2860
Q24645122-05FAB2BA-6152-4423-948B-87184F033A73Q24649530-4612AA73-A477-483E-80C2-554D8BC9F92BQ24651090-F41B62D5-1977-482F-8002-63C730377C54Q26738668-232954BB-7846-4DDB-85D5-1F2571912E80Q26741277-7687F8DD-5A24-4AB7-971F-4020F60D9E41Q26747699-BFC44BC0-8121-4518-933E-8CBA9935EF5EQ26798412-B5B736F4-43CC-4B33-85D5-0EC60ADD074EQ26852388-91CDC800-06E6-4D60-9B76-944DB61AE39DQ26861575-74E77554-ADF8-4C7F-8B8D-32B980EC4F39Q26863283-812194DC-30A9-48EE-A17E-65CBAD2459E5Q26864390-961942EC-533F-4118-96DE-53B7A83A936BQ27008070-68F356F6-F348-4D74-9D63-617EC4F03559Q29619918-EB4BE3D7-CFF6-4A38-886E-D308D2D97102Q30317628-398CC6BC-7DAD-401F-8A2C-5C6D9561B348Q33677054-3D3B06D7-808B-4996-9367-4951649CCEDBQ33709425-92CA5F2F-CDD7-4F4A-957B-ADEFEBCB56D7Q33886261-1CE36916-1119-4AEA-80A5-A51B15B5441EQ34039068-8E3BA2D0-FA6F-4803-9387-6B6E0DF5C488Q34158070-3582364B-6114-4060-8E1D-3FFE02027F87Q34180779-CF65F1A5-32AC-425F-B905-8284031D998AQ34284652-9C11C23B-DD0B-4762-A8D7-14963FA424A8Q34309004-CCAF9304-3168-4F86-BD08-B11E8898FC83Q34504202-354F3D0B-0A9F-4FDE-821B-C4C79F3B6266Q34590434-172EA369-C637-48BE-9ABE-A62B31DD5DAFQ34602552-6AE2170A-B059-4526-BA0E-316F38D73AAAQ34610121-88D8E5A8-3D65-4C7F-AA6F-4EF6B02AAB23Q34632056-B4EBDD75-3496-49F4-9CB0-92D78ECA009EQ34669820-9019E3D9-2BEC-407C-ABFD-C67E8A260DA1Q34672927-0B8E2B47-62F0-4861-BEDF-FA117CC223B2Q34686161-BD2D1929-DAAD-46E5-A132-D7DA019A9911Q34687216-072BEECE-D865-4E8D-AF60-BE0C4B1C66B0Q34787754-5E187ECE-D94B-4EA3-9682-4962F8517D3DQ34906723-0979C113-AEDD-483A-80DD-7FF856279E9CQ35076264-19DDD866-485C-4C76-9AA9-9AC32971ADA1Q35128716-1B33652E-7646-4EBA-9D9C-1CDA77887981Q35172536-F56736F2-1DB3-44C6-9CB5-51F3CBB72026Q35503645-660337AB-57AB-477B-910A-69B9F3BAC4EBQ35582228-BCD8B751-EC02-4496-8BB9-32B8955DFFA8Q35584269-6828DB8B-9058-428E-8826-5988E57B09A0Q35887768-ADBC6323-6AAC-4EB5-B73B-5932B6A4BB4C
P2860
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
@ast
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
@en
type
label
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
@ast
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
@en
prefLabel
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
@ast
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
@en
P2093
P1476
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
@en
P2093
F H Valone
M V Peshwa
P304
P356
10.1200/JCO.2000.18.23.3894
P407
P577
2000-12-01T00:00:00Z